PRONAI THERAPEUTICS INC. announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1). PNT737 is being investigated in two recently initiated Phase I clinical trials, currently sponsored and...
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
